AstraZeneca Updates on Olaparib and TC-5214 Development Programs

AstraZeneca Press Release (12/20/11)
AstraZeneca has announced that its investigational compound olaparib will not progress into Phase III development for the maintenance treatment of serous ovarian cancer. In addition, AstraZeneca announced that the second RENAISSANCE Phase III study of TC-5214 for patients with major depressive disorder did not meet its primary end point.

Read the complete article

Share |

Sponsor Highlights